Literature DB >> 29098307

[Therapeutic approach in oligometastatic gastric and esophageal cancer].

T Schmidt1, S P Mönig2.   

Abstract

The therapeutic approach to patients with oligometastatic gastric cancer and esophageal cancer is currently undergoing a shift towards a more aggressive therapy including surgical resection. In the current German S3 guidelines surgical treatment of metastatic disease is not recommended; however, nowadays interdisciplinary tumor boards have to evaluate such patients increasingly more often. On an individual basis a radical surgical resection of the primary tumor and the metastases is considered and performed in patients who respond well to multimodal chemotherapy concepts. In this review article the currently available data from the literature are discussed and a foundation for individually extended surgical approaches is presented. Together with the currently available results of the FLOT 3 study and the mostly retrospective studies, it seems to be possible to identify patients who would profit from such an aggressive treatment. In the future randomized prospective studies, such as the RENAISSANCE/FLOT 5 study and the GASTRIPEC study will have to evaluate whether an aggressive surgical therapy within multimodal therapy concepts of metastatic gastric and esophageal carcinomas is warranted.

Entities:  

Keywords:  Adenocarcinoma of the gastroesophageal junction; Metastasectomy; Metastasis; Multimodal therapy; Oligometastases

Mesh:

Year:  2017        PMID: 29098307     DOI: 10.1007/s00104-017-0548-3

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  66 in total

1.  Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery.

Authors:  Brian Badgwell; Sinchita Roy-Chowdhuri; Yi-Ju Chiang; Aurelio Matamoros; Mariela Blum; Keith Fournier; Paul Mansfield; Jaffer Ajani
Journal:  J Surg Oncol       Date:  2015-04-14       Impact factor: 3.454

2.  Response to preoperative chemotherapy predicts survival in patients undergoing hepatectomy for liver metastases from gastric and esophageal cancer.

Authors:  Andreas Andreou; Luca Viganò; Giuseppe Zimmitti; Daniel Seehofer; Martin Dreyer; Andreas Pascher; Marcus Bahra; Wenzel Schoening; Volker Schmitz; Peter C Thuss-Patience; Timm Denecke; Gero Puhl; Jean-Nicolas Vauthey; Peter Neuhaus; Lorenzo Capussotti; Johann Pratschke; Sven-Christian Schmidt
Journal:  J Gastrointest Surg       Date:  2014-08-27       Impact factor: 3.452

3.  Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis.

Authors:  Leila Sisic; Moritz J Strowitzki; Susanne Blank; Henrik Nienhueser; Sara Dorr; Georg Martin Haag; Dirk Jäger; Katja Ott; Markus W Büchler; Alexis Ulrich; Thomas Schmidt
Journal:  Gastric Cancer       Date:  2017-07-24       Impact factor: 7.370

4.  REGATTA trial: a call for the USA and Europe.

Authors:  Domenico D'Ugo; Ferdinando C M Cananzi; Roberto Persiani; Annamaria Agnes; Alberto Biondi
Journal:  Lancet Oncol       Date:  2016-03-02       Impact factor: 41.316

5.  Chemotherapy and resection for gastric cancer with synchronous liver metastases.

Authors:  Lei Chen; Ming-Quan Song; Hui-Zhong Lin; Lin-Hua Hao; Xiang-Jun Jiang; Zi-Yu Li; Yu-Xin Chen
Journal:  World J Gastroenterol       Date:  2013-04-07       Impact factor: 5.742

6.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

7.  Surgical resection of hepatic metastases from gastric cancer: outcomes from national series in England.

Authors:  Sheraz R Markar; Hugh Mackenzie; Sameh Mikhail; Muntzer Mughal; Shaun R Preston; Nick D Maynard; Omar Faiz; George B Hanna
Journal:  Gastric Cancer       Date:  2016-03-03       Impact factor: 7.370

Review 8.  Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long-term Survival: Systematic Review and Pooled Analysis.

Authors:  Sheraz R Markar; Sameh Mikhail; George Malietzis; Thanos Athanasiou; Christophe Mariette; Mitsuru Sasako; George B Hanna
Journal:  Ann Surg       Date:  2016-06       Impact factor: 12.969

9.  Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis.

Authors:  Giorgi Nadiradze; Urs Giger-Pabst; Juergen Zieren; Dirk Strumberg; Wiebke Solass; Marc-André Reymond
Journal:  J Gastrointest Surg       Date:  2015-10-28       Impact factor: 3.452

Review 10.  Hepatectomy for liver metastases from gastric cancer: a systematic review.

Authors:  Ying-Yang Liao; Ning-Fu Peng; Di Long; Peng-Cheng Yu; Sen Zhang; Jian-Hong Zhong; Le-Qun Li
Journal:  BMC Surg       Date:  2017-02-13       Impact factor: 2.102

View more
  4 in total

Review 1.  [Oligometastases in gastric and esophageal cancer : Current clinical trials and surgical concepts].

Authors:  S Beckert; A Königsrainer
Journal:  Chirurg       Date:  2018-07       Impact factor: 0.955

Review 2.  Oligometastatic Gastroesophageal Adenocarcinoma: Molecular Pathophysiology and Current Therapeutic Approach.

Authors:  Jin-On Jung; Henrik Nienhüser; Nikolai Schleussner; Thomas Schmidt
Journal:  Int J Mol Sci       Date:  2020-01-31       Impact factor: 5.923

Review 3.  Multimodal treatment in oligometastatic gastric cancer.

Authors:  Mickael Chevallay; Charles-Henri Wassmer; Pouya Iranmanesh; Minoa K Jung; Stefan P Mönig
Journal:  World J Gastrointest Oncol       Date:  2022-02-15

Review 4.  Esophageal Tumor Microenvironment.

Authors:  Henrik Nienhüser; Naita Wirsik; Thomas Schmidt
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.